Philippines Infectious Disease Therapeutics Market Analysis

Philippines Infectious Disease Therapeutics Market Analysis


$ 3999

By 2030, it is anticipated that the Philippines infectious disease therapeutics market will reach a value of $385.2 Mn from $263.71 Mn in 2022, growing at a CAGR of 4.9% during 2022-2030. The Infectious Disease Therapeutics in the Philippines is dominated by a few domestic pharmaceutical companies such as Glovax Biotech, United Laboratories and Pharex Health Corporation. The Infectious Disease Therapeutics market in the Philippines is segmented into different therapeutic areas and different diseases type. The major factors affecting the Philippines' infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious disease treatment in various areas of the Philippines.

ID: IN10PHPH038 CATEGORY: Pharmaceuticals GEOGRAPHY: Phillipines AUTHOR: Dr. Vishwa Modhia

Buy Now

Philippines Infectious Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Philippines infectious disease therapeutics market will reach a value of $385.2 Mn from $263.71 Mn in 2022, growing at a CAGR of 4.9% during 2022-2030.

The Philippines is a low-middle-income developing country in Southeast Asia in the western Pacific Ocean. According to the World Factbook, the Philippines is particularly susceptible to infectious diseases. Bacterial diarrhoea, hepatitis A, and typhoid fever are examples of food or waterborne infections. Leptospirosis is a water-borne infection that is common in the Philippines.

The Philippines is also involved in vaccine development, with the Ministry of Health and the Research Institute for Tropical Medicine (RITM) in charge of vaccine development and delivery. The RITM manufactures a variety of vaccinations, including those against polio, measles, and dengue fever. The Philippines' government spends 5.1% of its GDP on healthcare.

Philippines Infectious Disease Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers Analysis

The Philippines has a high prevalence of infectious diseases, with tuberculosis, malaria, and dengue fever being the most frequent. The development and availability of infectious illness treatments are critical for preventing and treating these ailments. In the Philippines, the situation is extremely challenging - the WHO estimates that in 2019, up to 1 Mn Filipinos had active TB, the third highest frequency in the world. Every day, over 70 people in the country die as a result of this completely treatable condition. The Philippines' Business Process Outsourcing (BPO) industry is thriving. These aspects could boost Philippine's infectious disease therapeutics market.

Market Restraints

According to the Philippine National Health Research System (PNHRS), tuberculosis (TB) is most prevalent among the urban poor, who frequently lack access to health care. Although the Filipino government has taken attempts to reduce the cost of TB treatment for low-income households through its aforementioned National Tuberculosis Program, 2022 research revealed that 42 % of TB households were still experiencing "catastrophic expenditures" linked with the condition. Certain infectious diseases may have a limited study focus, notably those that primarily afflict poor nations or have relatively low incidence rates in the Philippines. The Philippines has high levels of income disparity and underemployment, which leads to expatriation. These factors may deter new entrants into the Philippines infectious disease therapeutics market.

Competitive Landscape

Key Players

  • Glovax Biotech - Glovax Biotech is a Filipino biotechnology company that develops and manufactures vaccines for infectious diseases, including COVID-19. The company is also involved in the production of diagnostic tests and other medical products
  • United Laboratories (Unilab) - Unilab is a Filipino pharmaceutical company that develops and manufactures a range of therapeutics, including antibiotics and antivirals. The company has also been involved in the development of treatments for infectious diseases such as HIV/AIDS and tuberculosis
  • Pharex Health Corporation - Pharex Health Corporation is a Filipino pharmaceutical company that develops and manufactures a range of drugs, including antibiotics and antivirals
  • LRI-Therapharma - LRI-Therapharma is a Filipino pharmaceutical company that develops and manufactures a range of drugs, including antibiotics and antivirals and treatments for infectious diseases such as HIV/AIDS and hepatitis C

Recent Notable Updates

February 2023: Tanco-led Maestro Holdings and Reliance United, a subsidiary of United Laboratories (Unilab), the leading pharmaceutical company in the Philippines and Southeast Asia, have formed a partnership that will provide access to Reliance United’s full-service Healthfirst Clinic to members of the pioneering health maintenance organisation PhilCare. The collaboration validates the two companies' dedication to providing the greatest healthcare services to their clients and solidifies their position as two of the most active institutions in the country's healthcare market.

Healthcare Policies and Reimbursement Scenarios

The Food and Drug Administration regulates infectious illness medicines in the Philippines (FDA). Through the Philippine Health Insurance Corporation, the government offers subsidised healthcare services to the populace, including treatments for infectious diseases (PhilHealth). PhilHealth is responsible for overseeing the national health insurance programme, which offers coverage for a range of healthcare services, including medicines and treatments for infectious diseases.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Infectious Disease Therapeutics Segmentation

By Mode of Treatment (Revenue, USD Billion):

  • Vaccines
  • Drugs

By Applications (Revenue, USD Billion):

  • HIV/AIDS
  • Influenza
  • Hepatitis
  • Malaria
  • Tuberculosis
  • Others

By Disease Type (Revenue, USD Billion):

  • Viral Diseases
  • Bacterial Diseases
  • Fungal Diseases
  • Parasitic Diseases
  • Others

By Target Organism (Revenue, USD Billion):

  • Antibiotics
  • Antivirals
  • Antifungals
  • Anti-Parasitic
  • Others

By End User (Revenue, USD Billion):

  • Hospitals and Clinics
  • Ambulatory Care Centers
  • Others

Insights10 will provide you with the reports within 10 key parameters which are:

  1. Market Overview
  2. Market Growth Drivers & Restraints
  3. Epidemiology of Disease Type
  4. Market Segmentation
  5. Market Share
  6. Competitive Landscape
  7. Key Company Profiles
  8. Healthcare Policies & Regulatory Framework
  9. Reimbursement Scenario
  10. Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

 

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

 

 

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and  Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

 

 

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing the regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue/volume
  • ​Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.

By 2030, it is anticipated that the Philippines infectious disease therapeutics market will reach a value of $385.2 Mn from $263.71 Mn in 2022, growing at a CAGR of 4.9% during 2022-2030.

In the Philippines, the regulation of infectious disease therapeutics is overseen by the Food and Drug Administration (FDA). The government provides subsidized healthcare services to the population, including treatments for infectious diseases, through the Philippine Health Insurance Corporation (PhilHealth).

The Infectious Disease Therapeutics in the Philippines is dominated by a few domestic pharmaceutical companies such as Glovax Biotech, United Laboratories and Pharex Health Corporation.


This report addresses

  • Intelligent insights to take informed business decisions
  • Qualitative, acute and result oriented market analysis
  • Market size and forecasts from 2022 to 2030
  • Opportunities for expansion and in-depth market analysis
  • Segmentation and regional revenue forecasts
  • Analysis of the market share and competitive landscape
  • Strategic Recommendations to chart future course of action
  • Comprehensive Market Research Report in PDF and PPT formats

Need more?

  • Ask our analyst how this study was put together to learn more
  • Discuss additional requirements as part of the free customisation
  • Add more countries or regions to the scope 
  • Get answers to specific business questions 
  • Develop the business case to launch the product
  • Find out how this report may influence your business revenue
Last updated on: 13 March 2023
Updated by: Riya Doshi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up